A Phase II Study in Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) of Total Lymphoid Irradiation (TLI) and Antithymocyte Globlulin (ATG) Followed by Matched Allogeneic Hematopoietic Transplantation as a Consolidation to Autologous Hematopoietic Cell Transplantation (AHCT).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Antithymocyte globulin (Primary)
- Indications Diffuse large B cell lymphoma; Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 14 May 2018 Biomarkers information updated
- 02 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jul 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.